Table 4. Analysis of factors associated with any graft functional decline 12 months after the diagnosis and long-term graft loss in PVAN patients.

	Univariate analysis a		Multivariate analysis
	OR& RR (95% CI)	p value	OR&RR (95% CI)	p value
Any graft functional decline 12 months after the diagnosis
Scr at diagnosis	1.01(1.00–1.02)	0.028	1.01(1.00–1.03)	0.194
Reduction of viremia by 90%	0.037(0.005–0.297)	0.002	8.74(0.06–1240.53)	0.391
Clearance of viremia	0.044(0.007–0.290)	0.001	0.01(0.00–1.62)	0.077
Rapid reduction of BK DNAuria	0.139(0.025–0.762)	0.023	0.06(0.003–1.06)	0.055
Pathological parameters
Classification of PVAN	4.68(1.21–18.17)	0.026	0.44(0.02–11.62)	0.622
i score	7.15(1.73–29.56)	0.007	20.16(1.11–365.57)	0.042
ci score	2.41(1.09–5.34)	0.030	4.48(0.18–114.85)	0.365
ct score	2.42(1.02–5.73)	0.045	0.04(0–3.49)	0.157
Long-term graft loss
Scr at diagnosis	1.01(1.00–1.01)	0.008	0.99(0.96–1.01)	0.262
BKV replication
Clearance of viremia	0.08(0.02–0.29)	0.000	2.91(0.02–445.86)	0.677
Reduction of BKV DNAuriA by 90%	0.09(0.03–0.30)	0.000	0.007(0–1.39)	0.066
Reduction of viremia by 90%	0.10(0.03–0.35)	0.000	0.073(0.001–5.35)	0.232
Rapid clearance of of viremia	0.15(0.03–0.73)	0.018	0.01(0–2×10126)	0.962
Rapid reduction of of viremia	0.19(0.04–0.88)	0.034	570.28(0–2×10132)	0.967
Pathological parameters
Classification(A/B/C))	7.36(2.61–20.76)	0.000	162.16(2.12–12385.55)	0.021
cy score	2.28(1.23–4.25)	0.009	9.63(0.72–128.83)	0.087
i score	49.73(5.54–446.9)	0.000	46988.14(2.49–9×108)	0.032
ci score	3.23(1.39–7.47)	0.006	2.18(0.11–43.70)	0.611
ct score	3.56(1.36–9.32)	0.010	0.076(0.001–4.18)	0.207

^aLogistic and Cox regression analysis were performed to determine which risk factors affected any graft functional decline 12 months after the diagnosis and long-term graft loss respectively. Results were expressed as odds ratios (OR) or relative risk (RR) with respective 95% confidence intervals.